Quality management system modernisation will be the focus of a joint presentation by Kivo and CRISPR Therapeutics at the DIA Global Annual Meeting 2026, where the organisations will discuss the implementation of a new Quality Management System (QMS) in 52 days.
The session will explore how CRISPR Therapeutics adopted a new quality management infrastructure using technology from Kivo while maintaining compliance requirements and supporting operational agility.
The presentation is scheduled to take place during the DIA Global Annual Meeting in Philadelphia on 15 June 2026.
Focus on modernising quality management systems
The session, titled Nothing Changes Unless We Do – Implementing QMS with CRISPR Therapeutics in 52 Days, will feature Kate Ellmer, Executive Director of Quality and PV Operations at CRISPR Therapeutics, and Chris Xistris, Vice President of Services at Kivo.
According to the organisations, the discussion will focus on practical lessons learned from implementing a modern quality management system within a compressed timeframe.
The project reflects a broader trend across the pharmaceutical and biotechnology sectors as organisations seek alternatives to legacy enterprise software platforms that can require lengthy implementation periods and significant operational resources.
Growing demand for digital quality infrastructure
As biotechnology and pharmaceutical companies continue to scale development programmes, demand is increasing for systems capable of supporting regulatory, clinical and quality operations while maintaining compliance.
Digital quality management systems are increasingly being used to manage controlled documentation, training records, inspection readiness, quality events and process workflows across drug development programmes.
Read more Life Sciences Global News coverage of digital transformation and regulatory technology in life sciences.
Cell and gene therapy organisations seek operational flexibility
Kivo stated that interest has been particularly strong among cell and gene therapy developers and rare disease organisations, where smaller operational teams often require scalable infrastructure without the complexity associated with traditional enterprise platforms.
CRISPR Therapeutics is among a growing number of biotechnology companies working to balance rapid innovation with regulatory and quality requirements as advanced therapies move through development and commercialisation pathways.
DIA 2026 presentation details
The session will take place at the Pennsylvania Convention Center in Philadelphia on 15 June 2026 from 1:05pm to 1:35pm.
DIA Global Annual Meeting is one of the life sciences industry’s largest events, bringing together pharmaceutical companies, biotechnology organisations, regulators, technology providers and research professionals to discuss developments across drug development and healthcare innovation.
Frequently Asked Questions
What is a Quality Management System (QMS)?
A Quality Management System is a structured framework used by life sciences organisations to manage quality processes, compliance requirements, documentation and regulatory obligations.
Who is presenting at DIA 2026?
The session will feature Kate Ellmer from CRISPR Therapeutics and Chris Xistris from Kivo.
What is the focus of the presentation?
The presentation examines how CRISPR Therapeutics implemented a modern Quality Management System in 52 days while supporting compliance and operational requirements.
Why are life sciences companies modernising QMS platforms?
Many organisations are seeking more flexible and scalable systems that can support growing regulatory, clinical and quality operations while reducing implementation complexity.
When is the session taking place?
The session is scheduled for 15 June 2026 during the DIA Global Annual Meeting in Philadelphia.
Further information is available from Kivo and CRISPR Therapeutics.
